Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2008

View Archived Issues

Pfizer compounds reveal potential of c-Met inhibition for cancer treatment

Deciphera describes activity and optimization of bcr-Abl kinase inhibitor DCC-2036

Novel therapeutic agents for cancer covered in recent patent literature

Bristol-Myers Squibb develops a novel and potent statin with reduced myotoxicity

Org-52186 shows potential for treating anxiety and depression

Preclinical data on Pfizer's alpha2delta ligand PD-0200390 reported

Cleveland BioLabs completes enrollment in phase II clinical trial of Curaxin in prostrate cancer

Dutch health authorities license Vaccinogen to manufacture OncoVAX anticolon cancer vaccine

Cytopia and Cancer Therapeutics enter anticancer drug development collaboration

Dainippon Sumitomo initiates phase I clinical development of immune response modifier

iCo Therapeutics acquires worldwide rights to iCo-009 for systemic fungal infections

Microbix forms Klarogen Biotherapeutics and acquires ImaRx's clot busting drug urokinase

Mistral Pharma not to pursue combination with U.S. specialty pharmaceutical company

OrthoLogic reports positive safety data from phase I clinical trial of AZX-100

Endogenous inhibitor of corneal lymphangiogenesis shows potential in corneal transplantation model

Dana-Farber Cancer Institute initiates phase I trial of EntreMed's ENMD-2076

New class of topical antioxidants for the treatment of retinal disorders reported by Sirion

FDA grants approval to Osiris for expanded access treatment program for Prochymal in GVHD

BiPar expands phase II clinical trial programs for BSI-201 to include ovarian cancer

FDA approves Strattera for maintenance of ADHD in children and adolescents

Recent patents disclose new agents for endocrine disorders

FDA grants orphan drug designation for palifosfamide in soft tissue sarcoma

Medarex initiates phase II trials in ulcerative colitis and rheumatoid arthritis

Active Biotech moves Anyara into phase III in renal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...